Medicare AdvantagePrior AuthLow impact
Duobrii® (halobetasol propionate and tazarotene) (Revised)
Humana·Dermatology·Medicare Advantage
Effective date
Jan 1, 2021
We identified it
Jun 25, 2026
Summary
Humana updated its prior authorization policy for Duobrii (halobetasol propionate and tazarotene) lotion for plaque psoriasis, effective January 1, 2021, with a revision date of February 25, 2026. The policy requires prior authorization and mandates that members have a diagnosis of plaque psoriasis AND previous treatment with, intolerance, or contraindication to tazarotene topical cream before approval. This is a routine policy maintenance update with no substantive coverage changes from the original effective date.
Action Required
No immediate action required. This is a policy revision/reconfirmation rather than a new policy change. The prior authorization requirement for Duobrii has been in effect since January 1, 2021. Billing team should verify current system rules align with the two approval criteria: (1) plaque psoriasis diagnosis, and (2) prior tazarotene treatment/intolerance/contraindication. If not currently configured, update billing system to require prior authorization and documentation of tazarotene history before processing Duobrii claims. For medically billed requests, providers should reference www.humana.com/PAL for applicable preauthorization codes.